GleamWall
中文EN

LEXX Lexaria Bioscience Corp.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1348362 · Fiscal year ends 08/31

Financial factors as of 2026-05-31 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-68.5%
TTM net income YoY32.1%
TTM EPS YoY50.0%
Revenue 3-yr CAGR-14.2%
Net income 3-yr CAGR—

Margins

Gross margin100.0%
Operating margin-3,973.2%
Net margin-3,985.6%
FCF margin-3,848.6%
EBITDA margin-3,960.4%

Returns

ROE-150.3%
ROA-134.2%
ROIC (approx.)-553.9%
Asset turnover0.03x

Leverage & solvency

Liabilities / assets9.1%
Debt / equity0.00x
Current ratio10.60x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.96x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue21.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-05-312026Q22026-02-282026Q12025-11-302025Q4*2025-08-312025Q32025-05-312025Q22025-02-282025Q12024-11-302024Q4*2024-08-31
Income statement
Revenue$0$20,000$0$174,000$174,000$174,000$183,923$84,000
Cost of revenue$0$0$0$0$0$0$2,720$0
Gross profit$0$20,000$0$174,000$174,000$174,000$181,203$84,000
R&D expense$970,834$475,388$671,340$1.88M$2.72M$1.69M$1.95M$967,206
SG&A expense$1.02M$996,515$902,291$980,477$1.21M$1.24M$918,690$1.32M
Operating income-$1.99M-$1.45M-$1.57M-$2.69M-$3.75M-$2.75M-$2.69M-$2.20M
Pretax income-$1.99M——-$2.70M-$3.79M———
Income tax$14$2,598$1,791—$0$0$0—
Net income-$1.99M-$1.45M-$1.60M-$2.70M-$3.79M-$2.71M-$2.70M-$2.18M
EBITDA-$1.98M-$1.44M-$1.56M-$2.70M-$3.72M-$2.75M-$2.66M-$2.19M
EPS (diluted)-0.08-0.06-0.07—-0.21-0.15-0.16—
Weighted avg. shares (diluted)24.81M24.44M21.38M—18.30M17.51M16.67M—
Banking
Net interest income———————$6,993
Balance sheet
Cash & equivalents$3.50M$5.10M$4.30M$1.80M$4.59M$6.47M$8.08M$6.50M
Short-term investments$142,103$141,266$143,267$143,267$33,540$73,915$39,875$55,807
Receivables$48,998$42,029$88,044$368,358$358,129$331,166$263,491$154,477
Current assets$4.06M$5.77M$5.36M$3.47M$5.81M$7.72M$8.83M$7.90M
PP&E, net$229,017$242,931$216,120$228,129$240,139$261,890$270,621$254,709
Intangibles$339,016$318,058$308,060$307,818$516,420$506,180$505,373$516,676
Total assets$4.78M$6.49M$6.05M$4.18M$6.74M$8.68M$9.79M$8.87M
Current liabilities$383,412$214,671$1.46M$1.49M$1.49M$1.82M$297,798$1.10M
Total liabilities$437,091$276,997$1.53M$1.57M$1.57M$1.92M$399,718$1.21M
Shareholders' equity$4.74M$6.60M$4.91M$2.99M$5.55M$7.14M$9.77M$8.04M
Shares outstanding24.79M24.89M22.23M19.56M19.46M17.45M17.45M19.56M
Cash flow statement
Operating cash flow-$1.64M-$2.16M-$984,098-$2.64M-$3.58M-$1.50M-$2.73M-$1.89M
Capital expenditure$0$40,816$0$1-$1$1$24,645$43,014
Free cash flow-$1.64M-$2.20M-$984,098-$2.64M-$3.58M-$1.50M-$2.75M-$1.93M
Investing cash flow-$27,089-$53,909-$5,099-$157,878-$19,443-$27,894-$37,804-$69,587
Financing cash flow$0$3.04M$3.47M$0$1.69M$11,720$4.35M$0
Depreciation & amortization$13,914$14,005$12,009-$15,202$30,955$2,277$33,195$16,370
Stock-based compensation$92,944$74,895$74,895$122,724$470,136$167,219$99,415$96,510

Free plan shows the latest 8 periods; Pro shows all 68 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.